MHRA Field Safety Notices Update: Critical Compliance for UK Medical Device Operators
The MHRA has issued its latest Field Safety Notices, covering the period 28 September to 2 October 2026. UK medical device manufacturers and distributors must immediately review these alerts and action all directives to maintain regulatory compliance and supply chain integrity.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 09 October 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its weekly compilation of Field Safety Notices (FSNs) for the period between 28 September and 2 October 2026. This release, dated 9 October 2026, includes critical product alerts from manufacturers such as Alba Bioscience, B Braun, Medtronic, Philips, Reliance Medical, Roche Diagnostics, Silvalea, and TRACOE. Operators in the UK medical device sector, including manufacturers, distributors, and healthcare providers, are mandated by the MHRA to action all FSNs immediately upon receipt from the manufacturer. The MHRA’s publication serves solely as an informational register, not as the primary notification mechanism.
Key FSNs identified in this update include specific models of diagnostic equipment (e.g., Roche Diagnostics' cobas c 303 analytical unit, Philips' Radiography 7000 M X-ray system), surgical instruments (Medtronic's Auto Suture™ Structural Balloon & Blunt Tip Trocar), and patient care items (Silvalea's Dress Sling Poly Grey Ex Ex Large, TRACOE's Tracheostomy tubes). Each FSN details specific product identifiers, including model numbers and MHRA reference codes, such as 40977655 for Alba Bioscience's ORTHO Sera Anti-Fyb and 40973817 for B Braun's RV1000NC SAFSITE VENTIL. These notices typically relate to product safety, performance, or quality issues that necessitate corrective actions, ranging from user advisories to product retrieval or modification. Manufacturers are directly responsible for communicating these FSNs to all affected parties within their distribution network.
What this means for United Kingdom
UK medical device manufacturers must have robust post-market surveillance and recall protocols to meet the MHRA's stringent FSN requirements. Procurement teams should immediately verify that all medical device suppliers are monitoring FSNs and providing timely updates. Brand owners relying on third-party manufacturers for medical devices face increased liability if FSNs are not actioned promptly; non-compliance risks immediate product withdrawal and potential litigation. Manufacturers must budget for rapid response capabilities, including potential stock quarantine and expedited reformulation or replacement, to minimise market disruption and protect their CE/UKCA marking compliance status. This directly impacts operational expenditure and supply chain resilience.
The onus remains on the regulated entities to liaise directly with the issuing manufacturer for detailed instructions and to ensure full compliance. Failure to implement prescribed actions from an FSN can lead to severe regulatory penalties, including product removal from the market and legal repercussions for negligence in patient safety. This is distinct from broader MHRA recalls, as FSNs often require specific, targeted actions rather than a blanket market withdrawal.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.